Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review.
Armenian P, Vo KT, Barr-Walker J, Lynch KL.
Neuropharmacology. 2018 May 15;134(Pt A):121-132. doi: 10.1016/j.neuropharm.2017.10.016. Epub 2017 Oct 14.
Are opioid receptor antagonists adequate for "Opioid" overdose in a changing reality?
Peppin JF, Pergolizzi JV Jr, Dahan A, Raffa RB.
J Clin Pharm Ther. 2021 Aug;46(4):861-866. doi: 10.1111/jcpt.13320. Epub 2021 Apr 28.
Naloxone nasal spray.
[No authors listed]
Drug Ther Bull. 2019 Sep;57(9):137-140. doi: 10.1136/dtb.2019.000035. Epub 2019 Jul 11.
Naloxone.
Handal KA, Schauben JL, Salamone FR.
Ann Emerg Med. 1983 Jul;12(7):438-45. doi: 10.1016/s0196-0644(83)80343-6.
Fentanyl crisis in Europe and Switzerland: current situation and response.
Iuga R, Robet T, Favrod-Coune T, Khazaal Y, Penzenstadler L, Zullino D.
Rev Med Suisse. 2025 Jun 4;21(921):1166-1168. doi: 10.53738/REVMED.2025.21.921.47325.
Intranasal Naloxone Administration.
Ortega R, Nozari A, Baker W, Surani S, Edwards M.
N Engl J Med. 2021 Mar 25;384(12):e44. doi: 10.1056/NEJMvcm2020745.
Naloxone.
Martin WR.
Ann Intern Med. 1976 Dec;85(6):765-8. doi: 10.7326/0003-4819-85-6-765.
Phenibut overdose.
Sankary S, Canino P, Jackson J.
Am J Emerg Med. 2017 Mar;35(3):516.e1-516.e2. doi: 10.1016/j.ajem.2016.08.067. Epub 2016 Sep 1.
Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model.
Stopera CJ, Bartlett MJ, Liu C, Esqueda A, Parmar R, Heien ML, Sherman SJ, Falk T.
Neuropharmacology. 2024 Oct 1;257:110047. doi: 10.1016/j.neuropharm.2024.110047. Epub 2024 Jun 16.
Opioid receptor-mediated control of acetylcholine release in human neocortex tissue.
Feuerstein TJ, Gleichauf O, Peckys D, Landwehrmeyer GB, Scheremet R, Jackisch R.
Naunyn Schmiedebergs Arch Pharmacol. 1996 Nov;354(5):586-92. doi: 10.1007/BF00170832.
